In the context of rising raw materials and increasing pressure on the appreciation of the renminbi, China's western medicine preparations have been booming in both import and export in 2010, and have maintained a good momentum of growth. In 2011, with the further recovery of the global economy and the recovery of the overall pharmaceutical market, we forecast that imports and exports of western medicine preparations will continue to grow steadily in the future.
First, the global pharmaceutical market has expanded and emerging markets have risen. According to IMS estimates, the global pharmaceutical market will grow by 5% to 7% in 2011 to US$880 billion, and 17 emerging pharmaceutical market countries will grow at a rate of 15% to 17% to reach US$170 billion to US$180 billion. The contribution of market growth is close to 50%. At the same time, due to the expiration of patents and the new round of budgetary expenditures, the developed countries' markets will face even more fierce challenges. All these have provided China with great opportunities for adapting to the market and providing resource advantages to Chinese companies.
Second, changes in the pharmaceutical landscape, China's share of patent drugs expired feast. At present, the pattern of the world's pharmaceutical market is changing at an unprecedented rate. During the period of 2011-2015, 77 billion US dollars in sales of patented drugs will expire. As a big country of generic drugs, the huge market capacity of patented drugs released from the world is undoubtedly a good factor for Chinese pharmaceutical companies. At the same time, the use of global pharmaceutical outsourcing to Asia, the transfer of good opportunities and unique advantages of raw materials to accelerate the pace of international certification, and constantly improve the ability to undertake the transfer and absorption of the international pharmaceutical industry, access to large-scale preparation of customized contracts, with partners to enter the marketing channel The international market will enhance the international influence of Chinese preparations.
Again, using policy advantages, increase the export of preparations. In order to accelerate the upgrading of the pharmaceutical industry and realize the export of pharmaceutical preparations from China to Europe, the United States, Japan, and other developed countries, the National Development and Reform Commission has started to formulate the "Special Item Industrialization of Major Grade Common Names" and the "Special Implementation Plan for Upgrading the Quality System of Pharmaceutical Preparations". , Through special funds and export tax rebate policy support to encourage the export of preparations. At the same time, China's pharmaceutical preparation companies can use the government's foreign aid platform and recommend foreign companies to export pharmaceutical preparations to expand their exports.
Finally, the Chinese pharmaceutical market is rapidly expanding and the import of preparations is expected to continue to expand. In 2011, the Chinese pharmaceutical market is expected to grow by about 25%, becoming the third largest pharmaceutical market in the world. The gradual implementation of the state's encouragement of import policies and the deepening of the new reform of medical reform will surely continue to drive the expansion of domestic demand. At the same time, multinational pharmaceutical companies will continue to increase their investment in China in order to mitigate the adverse effects of the economic and debt crises, and strive to occupy more market share, which will inevitably increase the import of pharmaceutical preparations. Local companies have also begun to accelerate the pace of industrial chain integration. Through improving the pharmaceutical sales network and building a pharmaceutical logistics platform, the use of the appreciation of the renminbi to facilitate the import of opportunities, and continuously improve the domestic market share.
It is estimated that in 2011, the import and export volume of western medicine products in China will maintain a growth rate of around 20%, and the increase in exports will be higher than the increase in imports. It is worth noting that there are still many uncertainties in the policy and operating environment in 2011. The changing trend of RMB exchange rate and export tax rebate will reduce the price competitiveness of Chinese products; the pressure of environmental protection will increase and the production cost will increase. To the company's production and operating capabilities and profit levels; serious overcapacity of some large varieties will inevitably cause dramatic price fluctuations in the international market, which will have a material impact on the import and export of western medicine products in China in 2011, increasing the uncertainty of the trend Sex.
First, the global pharmaceutical market has expanded and emerging markets have risen. According to IMS estimates, the global pharmaceutical market will grow by 5% to 7% in 2011 to US$880 billion, and 17 emerging pharmaceutical market countries will grow at a rate of 15% to 17% to reach US$170 billion to US$180 billion. The contribution of market growth is close to 50%. At the same time, due to the expiration of patents and the new round of budgetary expenditures, the developed countries' markets will face even more fierce challenges. All these have provided China with great opportunities for adapting to the market and providing resource advantages to Chinese companies.
Second, changes in the pharmaceutical landscape, China's share of patent drugs expired feast. At present, the pattern of the world's pharmaceutical market is changing at an unprecedented rate. During the period of 2011-2015, 77 billion US dollars in sales of patented drugs will expire. As a big country of generic drugs, the huge market capacity of patented drugs released from the world is undoubtedly a good factor for Chinese pharmaceutical companies. At the same time, the use of global pharmaceutical outsourcing to Asia, the transfer of good opportunities and unique advantages of raw materials to accelerate the pace of international certification, and constantly improve the ability to undertake the transfer and absorption of the international pharmaceutical industry, access to large-scale preparation of customized contracts, with partners to enter the marketing channel The international market will enhance the international influence of Chinese preparations.
Again, using policy advantages, increase the export of preparations. In order to accelerate the upgrading of the pharmaceutical industry and realize the export of pharmaceutical preparations from China to Europe, the United States, Japan, and other developed countries, the National Development and Reform Commission has started to formulate the "Special Item Industrialization of Major Grade Common Names" and the "Special Implementation Plan for Upgrading the Quality System of Pharmaceutical Preparations". , Through special funds and export tax rebate policy support to encourage the export of preparations. At the same time, China's pharmaceutical preparation companies can use the government's foreign aid platform and recommend foreign companies to export pharmaceutical preparations to expand their exports.
Finally, the Chinese pharmaceutical market is rapidly expanding and the import of preparations is expected to continue to expand. In 2011, the Chinese pharmaceutical market is expected to grow by about 25%, becoming the third largest pharmaceutical market in the world. The gradual implementation of the state's encouragement of import policies and the deepening of the new reform of medical reform will surely continue to drive the expansion of domestic demand. At the same time, multinational pharmaceutical companies will continue to increase their investment in China in order to mitigate the adverse effects of the economic and debt crises, and strive to occupy more market share, which will inevitably increase the import of pharmaceutical preparations. Local companies have also begun to accelerate the pace of industrial chain integration. Through improving the pharmaceutical sales network and building a pharmaceutical logistics platform, the use of the appreciation of the renminbi to facilitate the import of opportunities, and continuously improve the domestic market share.
It is estimated that in 2011, the import and export volume of western medicine products in China will maintain a growth rate of around 20%, and the increase in exports will be higher than the increase in imports. It is worth noting that there are still many uncertainties in the policy and operating environment in 2011. The changing trend of RMB exchange rate and export tax rebate will reduce the price competitiveness of Chinese products; the pressure of environmental protection will increase and the production cost will increase. To the company's production and operating capabilities and profit levels; serious overcapacity of some large varieties will inevitably cause dramatic price fluctuations in the international market, which will have a material impact on the import and export of western medicine products in China in 2011, increasing the uncertainty of the trend Sex.
With low-power, miniature size, the serial communication department range sensor with mm accuracy can measure up to 20m, 40m, 60m, 100m, 150m, 200m.
If you want to connect our laser range sensor boards together with your computer, you can directly choose the model with one USB connector.
In your project, you can use our distance sensor panel to measure a distance.
Serial Laser Distance Sensor,Serial Communication Laser Distance Sensor,Laser Range Sensor Boards,Distance Sensor Panel
Chengdu JRT Meter Technology Co., Ltd , https://www.cdlaserrangfinder.com